{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:16:22Z","timestamp":1788948982255,"version":"build-2803163510"},"reference-count":15,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100017689","name":"Guangdong Provincial People's Hospital","doi-asserted-by":"publisher","award":["KY012024198"],"award-info":[{"award-number":["KY012024198"]}],"id":[{"id":"10.13039\/501100017689","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.medj.2026.101104","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T15:09:02Z","timestamp":1778252942000},"page":"101104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["NSCLC: Five trials to watch"],"prefix":"10.1016","volume":"7","author":[{"given":"Wei-Chi","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Xin","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Yang Maggie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3611-0258","authenticated-orcid":false,"given":"Yi-Long","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2026.101104_bib1","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-025-01679-1","article-title":"Recent advances in therapeutic strategies for non-small cell lung cancer","volume":"18","author":"Su","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.medj.2026.101104_bib2","article-title":"Advances in molecular pathology and therapy of non-small cell lung cancer","volume":"10","author":"Huang","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.medj.2026.101104_bib3","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.trecan.2024.04.004","article-title":"Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer","volume":"10","author":"Abbosh","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.medj.2026.101104_bib4","doi-asserted-by":"crossref","DOI":"10.1186\/s40164-025-00637-4","article-title":"New exploration of KRASG12D inhibitors and the mechanisms of resistance","volume":"14","author":"Li","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.medj.2026.101104_bib5","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2402614","article-title":"Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC","volume":"391","author":"Lu","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2026.101104_bib6","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cllc.2023.09.008","article-title":"Adjuvant Therapy-Free Strategy for Stage IB to IIIA Non-Small-Cell Lung Cancer Patients After Radical Resection Based on Longitudinal Undetectable Molecular Residual Disease: Prospective, Multicenter, Single-Arm Study (CTONG 2201)","volume":"25","author":"Zhang","year":"2024","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.medj.2026.101104_bib7","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41571-023-00733-6","article-title":"Rare molecular subtypes of lung cancer","volume":"20","author":"Harada","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.medj.2026.101104_bib8","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.trecan.2023.07.010","article-title":"Next batter up! Targeting cancers with KRAS-G12D mutations","volume":"9","author":"Zeissig","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.medj.2026.101104_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/science.ads0239","article-title":"A neomorphic protein interface catalyzes covalent inhibition of RASG12D aspartic acid in tumors","volume":"389","author":"Weller","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.medj.2026.101104_bib10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa2512071","article-title":"Sacituzumab Tirumotecan in EGFR-TKI\u2013Resistant, EGFR-Mutated Advanced NSCLC","volume":"394","author":"Fang","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2026.101104_bib11","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1038\/s41591-025-03638-2","article-title":"Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1\/2 and phase 2 trials","volume":"31","author":"Zhao","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2026.101104_bib12","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1158\/1078-0432.CCR-23-2566","article-title":"TROP2 Is Associated with Primary Resistance to Immune Checkpoint Inhibition in Patients with Advanced Non-Small Cell Lung Cancer","volume":"30","author":"Bessede","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.medj.2026.101104_bib13","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1038\/s41591-025-03883-5","article-title":"First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial","volume":"31","author":"Hong","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2026.101104_bib14","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/S0140-6736(25)01848-3","article-title":"Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial","volume":"406","author":"Chen","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2026.101104_bib15","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-024-03040-4","article-title":"Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment","volume":"30","author":"Widman","year":"2024","journal-title":"Nat. Med."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634026001078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634026001078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T10:58:55Z","timestamp":1783162735000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634026001078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2666634026001078"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2026.101104","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NSCLC: Five trials to watch","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2026.101104","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101104"}}